论文与基金

订阅

MedSci主页 / 所有栏目 / 论文与基金

编辑谈投稿注意事项及正确对待审稿结果（英文PPT）

2009-03-23 MedSci原创 MedSci原创

PDF审稿SCI
关注

How to Publish in Biomedical JournalsTips of the Trade from an Itinerant Scientist and Journal Editor Steven J. Fliesler, PhDProfessor, Depts. of Ophthalmology and Pharmacological & Physiological

How to Publish in Biomedical Journals
Tips of the Trade from an Itinerant Scientist and Journal Editor

Steven J. Fliesler, PhD
Professor, Depts. of Ophthalmology and Pharmacological & Physiological Science, Saint Louis University School of Medicine
Section Editor, Experimental Eye Research
Editorial Board, the Journal of Lipid Research

编辑谈投稿注意事项及正确对待审稿结果.pdf

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947503, encodeId=baeb194e503d0, content=<a href='/topic/show?id=360f14591e2' target=_blank style='color:#2F92EE;'>#PPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14591, encryptionId=360f14591e2, topicName=PPT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Wed Jul 01 14:35:00 CST 2009, time=2009-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906692, encodeId=01fe19066927d, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat Jul 04 14:35:00 CST 2009, time=2009-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393021, encodeId=8cb813930218d, content=<a href='/topic/show?id=a4b84616527' target=_blank style='color:#2F92EE;'>#审稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46165, encryptionId=a4b84616527, topicName=审稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00622500123, createdName=12498a49m60暂无昵称, createdTime=Wed Mar 25 00:35:00 CST 2009, time=2009-03-25, status=1, ipAttribution=)]
    2009-07-01 ms5353107019656438

    #PPT#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1947503, encodeId=baeb194e503d0, content=<a href='/topic/show?id=360f14591e2' target=_blank style='color:#2F92EE;'>#PPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14591, encryptionId=360f14591e2, topicName=PPT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Wed Jul 01 14:35:00 CST 2009, time=2009-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906692, encodeId=01fe19066927d, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat Jul 04 14:35:00 CST 2009, time=2009-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393021, encodeId=8cb813930218d, content=<a href='/topic/show?id=a4b84616527' target=_blank style='color:#2F92EE;'>#审稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46165, encryptionId=a4b84616527, topicName=审稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00622500123, createdName=12498a49m60暂无昵称, createdTime=Wed Mar 25 00:35:00 CST 2009, time=2009-03-25, status=1, ipAttribution=)]
    2009-07-04 xlwang2691

    #注意事项#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1947503, encodeId=baeb194e503d0, content=<a href='/topic/show?id=360f14591e2' target=_blank style='color:#2F92EE;'>#PPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14591, encryptionId=360f14591e2, topicName=PPT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Wed Jul 01 14:35:00 CST 2009, time=2009-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906692, encodeId=01fe19066927d, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat Jul 04 14:35:00 CST 2009, time=2009-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393021, encodeId=8cb813930218d, content=<a href='/topic/show?id=a4b84616527' target=_blank style='color:#2F92EE;'>#审稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46165, encryptionId=a4b84616527, topicName=审稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00622500123, createdName=12498a49m60暂无昵称, createdTime=Wed Mar 25 00:35:00 CST 2009, time=2009-03-25, status=1, ipAttribution=)]
    2009-03-25 12498a49m60暂无昵称

    #审稿#

    0

相关资讯

如何撰写世界一流论文？

如何撰写世界一流论文 如何撰写世界一流论文.pdf

医学统计学实用教程(2) (medsci.cn)

本教程原是MedSci工作内部培训之用。但是我们每天都接收大量投递过来的论文，中间的统计错误非常多，因此，在小范围给部分用户讲过，或传阅过，反响很好。有些客户评价：“这是有史以业最强的统计学PPT”，虽然有些高抬，但愿这个PPT非常适合大家的需求，能够较为简单地告诉大家统计学的最基本，但最适用的方法和常识，助大家科研一辈之力。 因此，本PPT没有多少理论性的东西，另外，也没有多少公式，主要是基

一些中国稿件中的常见问题（浙江大学郑春仙教授）

A Study of Peer Error FeedbackZHENG Chun-xian1, 2(1. Foreign Languages School, Zhejiang University of Science and Technology, Hangzhou 310023;2. Foreign Languages School, Zhejiang University, Hangzhou

Cell Press编辑谈编辑工作

Cell Press编辑谈编辑工作.pdf

973标书：基于生物信息的药靶高通量筛选及功能研究

疾病对人类的健康和生存构成重大威胁，是世界各国面临的最重要的社会问题之一。当前和今后相当长的时期内药物将是疾病治疗的最主要手段，但由于历史、经济及观念等原因，与发达国家相比我国在药学相关基础研究，特别是创新药物的的基础研究和开发领域比较落后，导致医药产业基础较差，药品来源长期依赖于仿制和进口，每年进口药品达40亿美元以上。在中国加入WTO以后，一方面，由于知识

医学统计学实用教程(1) (medsci.cn)

本教程原是MedSci工作内部培训之用。但是我们每天都接收大量投递过来的论文，中间的统计错误非常多，因此，在小范围给部分用户讲过，或传阅过，反响很好。有些客户评价：“这是有史以业最强的统计学PPT”，虽然有些高抬，但愿这个PPT非常适合大家的需求，能够较为简单地告诉大家统计学的最基本，但最适用的方法和常识，助大家科研一辈之力。 因此，本PPT没有多少理论性的东西，另外，也没有多少公式